Navigation Links
Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
Date:8/29/2008

Experienced Executive Rina Wolf Well-Positioned to Help Drive Company

Growth

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Axial Biotech, Inc., a company poised to revolutionize spine care through the development of molecular diagnostic and motion preserving technologies, announced today that it has named Rina Wolf as the company's new Vice President of Reimbursement and Regulatory Affairs.

In her new role, Wolf will be responsible for the creation and implementation of reimbursement strategies and policies. As Axial's liaison to the laboratory community, she will continue her active role in matters relating to reimbursement and regulatory initiatives that impact molecular diagnostics.

John Climaco, President and CEO of Axial Biotech, stated, "One of the key components of Axial's future success will be achieving appropriate levels of insurance coverage for our products and Ms. Wolf's vast experience in this area is second to none. In addition, she brings to our company an unparalleled level of understanding of the complex and rapidly evolving regulatory landscape around molecular diagnostics."

In her most recent role as VP of Reimbursement and Regulatory Affairs with RedPath Integrated Pathology, Wolf was responsible for creating and managing all billing polices and activities, patient advocacy programs, and public/private payer coverage and contracting. This included gaining a favorable Coverage Article for PathFinderTG(R) with RedPath's MAC.

Prior to joining RedPath, Wolf was the Director of Reimbursement and Payer Relations for Genomic Health, Inc. where she helped to develop reimbursement strategies and programs that led to positive coverage policies with major third party payers, as well as a favorable local coverage determination from Genomic Health's Part B Medicare Carrier.

Wolf has also worked at Esoterix (now LabCorp) as Vice President of Contracts, and has worked at both Schering Plough and Searle Pharmaceuticals as a hospital and managed care specialty sales representative. She is a former President and board member of the California Clinical Laboratory Association and has been active with both ACLA and the Coalition for 21st Century Medicine. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.

"I am extremely excited to serve in this new capacity and for a company that has the potential to do so much to improve the quality of health care," said Wolf. "I believe Axial Biotech will provide the opportunity to assist in the fulfillment of the promise of molecular diagnostics and personalized medicine in the orthopedic spine arena. I am looking forward to putting the knowledge that I have accumulated to work to lessen reimbursement barriers for the innovative molecular diagnostic assays that the company is in the process of developing."

About Axial Biotech

Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign
5. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
6. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
10. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeqâ„¢ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
(Date:12/8/2016)... , Dec. 8, 2016 Savannah ... remediation technologies and selected NewTechBio,s NT-MAX Lake ... microbial based beneficial bacteria, in conjunction with Hexa ... correct deficiencies with National Pollutant Discharge Elimination System ... has experienced a steady history of elevated pH ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
Breaking Biology News(10 mins):